Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in case of acute severe hypertension. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.1
Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
Register today for one of our 2025 Webinars:
Blood Pressure Variability (BPV) in Stroke Care! CLEVIPREX is not indicated for the prevention or treatment of stroke.
Blood Pressure Variability (BPV) in Stroke Care! CLEVIPREX is not indicated for the prevention or treatment of stroke.
BP reduction in a range of patients and clinical settings1-5
Proven efficacy in:
- Perioperative hypertension
- Acute severe hypertension
- Intracerebral hemorrhage (ICH)
Established safety profile in multiple clinical trials2,3,6
CLEVIPREX demonstrated safety vs:
- Nicardipine in postoperative hypertension
- Sodium nitroprusside and nitroglycerin in perioperative hypertension
- Placebo in perioperative hypertension
Rapidly lowers arterial BP with fast onset and offset1
- Titratable, fast onset of action (within 2 minutes of initiation)
- ~1-minute half-life
- Metabolized independent of renal or hepatic function
Non–weight-based dosing1
CLEVIPREX dosing is also:
- A low infusion volume1
- Available as ready-to-use 50- and 100-mL vials1
Low-volume dosing option1
Excessive fluid intake may lead to adverse outcomes in critically ill patients7,8:
- Consider the results of the ECLIPSE trials
- See how infusion volumes varied between hypertensive agents in the postoperative setting
CLEVIPREX has not been studied or proven to impact fluid overload.
AIS Guideline Information
Cleviprex is a recommended option in the AIS guidelines since 2018.
ICH Guideline Information
AHA/ASA guidelines emphasize smooth, sustained blood pressure control for ICH.
Access CLEVIPREX Resources
Watch KOL videos or download guideline summaries, dosing cards and more.